Skip to content

Continuous Glucose Monitoring (CGM) in Prediabetes With Community Based Recruitment

Continuous Glucose Monitoring (CGM) in Prediabetes With Health Education Videos

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07477249
Acronym
G3
Enrollment
50
Registered
2026-03-17
Start date
2026-02-26
Completion date
2027-03-30
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Keywords

Prediabetes, Glucose control, Feedback, Health education, Artificial intelligence, Behavioral analysis

Brief summary

The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. The goal is to prevent transition to type 2 diabetes (T2D).

Detailed description

The primary objective of this new project is to enhance glycemic control in individuals with prediabetes and deter the progression to Type 2 Diabetes (T2D) within the Los Angeles (LA) County community. Our proposal involves conducting a Phase 0 intervention development study. This study will enlist a final sample of N=50 adults who speak English and/or Spanish, have non-clinical prediabetes, and test positive for prediabetes via a finger-prick A1c% screening. Participants will wear CGM devices for 20 days, with glucose data masked for the first 10 days and unmasked for the next 10 days. During the unmasked phase, participants will receive daily health education videos on their smartphones. The study will compare the duration of glucose excursions between the masked and unmasked phases to assess the impact of CGM feedback and health education on glucose regulation.

Interventions

DEVICECGM

The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.

Sponsors

David S Black, PhD
Lead SponsorOTHER
National Institute on Minority Health and Health Disparities (NIMHD)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Masking description

Participants are blinded to glucose values during Phase A. The CGM system generates automated records of glucose and does not require observation from an outcomes assessor. The investigator does not engage with participants and becomes aware of unmasking after trial is completed.

Intervention model description

Phase A / Phase B (AB) sequential condition design with CGM automated continuous glucose recording with glucose level masked and unmasked phases.

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 35 years of age or older * Willingness to wear CGM sensor * Prediabetes by finger prick blood A1C% or fasting glucose * Centers for Disease Control and Prevention (CDC) prediabetes risk test score of 5 or higher or recent prediabetes diagnosis from physician

Exclusion criteria

* Diagnosed with any disorder that interferes with glucose * Influential medical disorder/event affecting ability to participate in study * Incompatible smartphone device not pairing with Dexcom G6 app * Currently pregnant * Previously participated in other Continuous Glucose Monitoring studies * Having a planned trip outside California in the following 2 months

Design outcomes

Primary

MeasureTime frameDescription
Glucose levelsMaximum of 20 days of continuous wearMean glucose in mg/dL

Secondary

MeasureTime frameDescription
Time out of range > 140 mg/dL (TOR)Maximum of 20 days of continuous wearTime out of range \> 140 mg/dL (TOR)

Countries

United States

Contacts

CONTACTDavid S Black, PhD MPH
davidbla@usc.edu3234428223
CONTACTRuth Flores
rflores8@usc.edu
PRINCIPAL_INVESTIGATORDavid S Black, PhD MPH

University of Southern California Keck School of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026